These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 8988072

  • 1. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL.
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
    Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC.
    J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
    [Abstract] [Full Text] [Related]

  • 3. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
    Lilja JJ, Kivistö KT, Neuvonen PJ.
    Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
    [Abstract] [Full Text] [Related]

  • 4. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P.
    Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
    [Abstract] [Full Text] [Related]

  • 5. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
    Sarich TC, Schützer KM, Dorani H, Wall U, Kalies I, Ohlsson L, Eriksson UG.
    J Clin Pharmacol; 2004 Aug; 44(8):928-34. PubMed ID: 15286097
    [Abstract] [Full Text] [Related]

  • 6. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA.
    Am J Cardiol; 2004 Nov 01; 94(9):1140-6. PubMed ID: 15518608
    [Abstract] [Full Text] [Related]

  • 7. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB, Simvastatin Atorvastatin HDL Study Group.
    Curr Med Res Opin; 2001 Nov 01; 17(1):43-50. PubMed ID: 11464446
    [Abstract] [Full Text] [Related]

  • 8. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R, Williams RX, Guha-Ray DK, Sawyers WG, Braun SL, Rains KT.
    Clin Ther; 2006 Jan 01; 28(1):45-54. PubMed ID: 16490579
    [Abstract] [Full Text] [Related]

  • 9. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
    Jayaram S, Prasad HB, Sovani VB, Langade DG, Mane PR.
    J Indian Med Assoc; 2007 Mar 01; 105(3):142-5, 150. PubMed ID: 17824470
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan 01; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 11. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 01; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM.
    Antimicrob Agents Chemother; 2001 Dec 01; 45(12):3445-50. PubMed ID: 11709322
    [Abstract] [Full Text] [Related]

  • 13. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
    Backman JT, Luurila H, Neuvonen M, Neuvonen PJ.
    Clin Pharmacol Ther; 2005 Aug 01; 78(2):154-67. PubMed ID: 16084850
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.
    Clin Ther; 2007 Aug 01; 29(8):1692-705. PubMed ID: 17919550
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
    Jones PH, McKenney JM, Karalis DG, Downey J.
    Am Heart J; 2005 Jan 01; 149(1):e1. PubMed ID: 15660024
    [Abstract] [Full Text] [Related]

  • 16. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
    Lam HC, Chu CH, Wei MC, Keng HM, Lu CC, Sun CC, Lee JK, Chuang MJ, Wang MC, Tai MH.
    Exp Biol Med (Maywood); 2006 Jun 01; 231(6):1010-5. PubMed ID: 16741040
    [Abstract] [Full Text] [Related]

  • 17. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
    Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C.
    Ann Pharmacother; 2008 Jan 01; 42(1):9-15. PubMed ID: 18000162
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb 01; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.